Status:
COMPLETED
Effect of Two Versus Three Pneumococcal Conjugate Vaccinations
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
Netherlands: Ministry of Health, Welfare and Sports
Netherlands Vaccine Institute
Conditions:
Streptococcus Pneumoniae Infection
Eligibility:
All Genders
2-3 years
Phase:
PHASE3
Brief Summary
Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like meningitis,...
Detailed Description
Two(2 and 4 months) and three vaccinations (2,4 and 11 months) with 7-valent pneumococcal conjugate vaccine Prevnar in infants are presumed to provide about 90% protection against invasive pneumococca...
Eligibility Criteria
Inclusion
- Newborn infants eligible for participation in the national infant vaccination program in the Netherlands
Exclusion
- exclusion from the national vaccination program because of the presence of
- a medical condition requiring treatment that can interfere with the effect of vaccinations
- known or suspected allergy to components of the pneumococcal conjugate vaccine
- known or suspected immunodeficiency disease
- previous treatment with plasma or immunoglobulins
- previous vaccinations other than hepatitis B vaccinations
- coagulation disorders
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1005 Patients enrolled
Trial Details
Trial ID
NCT00189020
Start Date
June 1 2005
Last Update
August 22 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.